Matrixx Initiatives Withdraws Acquisition Offer for ProPhase Labs

      Matrixx Initiatives Withdraws Acquisition Offer for ProPhase Labs

$1.60 per share offer made on October 9, 2012 withdrawn

PR Newswire

BRIDGEWATER, N.J., Feb. 5, 2013

BRIDGEWATER, N.J., Feb. 5,2013 /PRNewswire/ -- Matrixx Initiatives, Inc., the
maker of the Zicam® cold, sinus and allergy line of products, announced today
that it has withdrawn the $1.60 per share offer it made in October to acquire
all of the outstanding shares of ProPhase Labs, Inc. (NASDAQ: PRPH) .

About Zicam Cold Remedy Products
Most cold medicines are designed to mask cold symptoms; however, Zicam Cold
Remedy is different. Zicam Cold Remedy products, which contain propriety
formulations of active ingredients zinc gluconate and zinc acetate, reduce the
duration of a cold when taken at the first sign of a cold (within the first 24
hours) and used as directed.

About Matrixx Initiatives, Inc.
Matrixx Initiatives, Inc. is engaged in the development and marketing of
over-the-counter health care products that utilize innovative drug delivery
systems. The company was acquired by HIG Capital in February 2011. Matrixx
Initiatives, Inc., manufactures and markets a full line of Zicam brand
homeopathic and allopathic OTC products, including new Zicam Cold Remedy Ultra
Crystals® in lemon-lime flavor, Zicam Cold Remedy Ultra Lozenges in honey
lemon flavor and Zicam Naturals® Cough Suppressant in honey lemon and mixed
berry flavored syrups. These products are available at retail with our
existing products Zicam Cold Remedy RapidMelts®, Zicam Cold Remedy Ultra
RapidMelts®, Zicam Cold Remedy Plus Liqui-Loz™, Zicam Cold Remedy Chewables,
Zicam Cold Remedy Oral Mist™, Zicam Allergy Relief™, Zicam Extreme Congestion
Relief™, and Zicam Sinus Relief™. For more information regarding Matrixx
products, please visit www.zicam.com.

SOURCE Matrixx Initiatives, Inc.

Website: http://www.zicam.com
Contact: M'lou Arnett, CEO, +1-908-344-3488
 
Press spacebar to pause and continue. Press esc to stop.